TORONTO - October 17, 2018 - (Newswire.com)
Join Maria Apkarian, Vice President of Early Clinical Development at WCCT Global, for a live webinar upcoming on Wednesday, Oct. 31, 2018, at 1 p.m. EDT (10 a.m. PDT).
Typically, early phase studies are conducted in somewhat of an isolated fashion, evaluating safety and pharmacokinetic/pharmacodynamic data in healthy volunteers (for non-oncology/rare disease studies) at clinical pharmacology units first. Target patient populations are occasionally incorporated into these early phase trials, with the objective of efficiently gaining insight into how the drug might perform during future testing. The issue with this model is that the studies are conducted mostly in a vacuum — at units that largely won’t be involved during Phases 2-3 — and without the oversight from the investigators who will be responsible for the patients and outpatient conduct in later stages of testing.
Incorporating patient populations into early phase studies is not a new practice, however, the current model of identifying one, or multiple, Phase 1 units with access to the patient population and conducting the study at that location still comes with many challenges. Fundamentally, Phase 1 sites don’t have access to historical records or charts to narrow down eligibility, as physician offices and late phase researchers do, and are reliant upon patient’s self-diagnosis, which leads to ineffective enrollment. While Phase 1 sites can expect a certain level of response to their marketing efforts, these may not be enough to meet the previously agreed-upon enrollment expectations and can be considerably inefficient and costly. Conversely, late phase researchers don’t have the Phase 1 unit inpatient capabilities that the project requires.
How can drug development companies overcome this hurdle? WCCT Global believes that the key to successful studies with patient populations is for sponsors to facilitate relationships between the sites hosting their early phase studies and the investigators they plan on utilizing for Phase 3. By involving late stage investigators into Phase 1 study planning and conduct, sponsor companies can achieve more successful patient enrollment, gain valuable input on future study designs based on investigator feedback, as well as identify potential risks and strategize on prevention for late stage programs. Furthermore, with this valuable information, financial investments can be better protected by producing early efficacy signals during early phase testing. In this webinar, WCCT Global will discuss strategies for the successful alignment of late-stage focused investigators and sites into the Phase 1 model and best practices for implementation.
For more information about this complimentary webinar, visit Sponsor-Facilitated Relationships Between Late Stage Researchers and Phase 1 Sites: A Novel Model for Early Phase Studies.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks, visit http://xtalks.com.
For information about hosting a webinar, visit http://xtalks.com/why-host-a-webinar/.
Contact:
Nima Rajan
Tel: +1 (416) 977-6555 ext 352
Email: nrajan@xtalks.com
Related Links
Webinar Details
About WCCT
Related Images
Press Release Service by Newswire.com
Original Source: Sponsor-Facilitated Relationships Between Late Stage Researchers and Phase 1 Sites: A Novel Model for Early Phase Studies, New Webinar Hosted by Xtalks
